And the Colorado M&A hits keep on coming…Merck & CO. (NYSE: MRK) announced the $1.1 billon acquisition of San Francisco headquartered Sirna Therapeutics, Inc. (NASDQ: RNAI). Why does an acquisition story about an acquirer from New Jersey and an acquiree from San Francisco make it onto the virtual pages of Colorado Life Science Deal Flow [...]

• 130http://clsdf.com/2006/10/when-it-rains-it-pours/When+It+Rains+It+Pours...2006-10-31+01%3A16%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), reported the final results from its completed Phase I trial for Sirna-027, a novel therapeutic for age-related macular degeneration (AMD). The Phase I study evaluated the safety, tolerability, and biological effect of single-ascending doses of Sirna-027 in patients with AMD. A total of 26 patients with active disease were enrolled [...]

• 114http://clsdf.com/2006/08/move-over-macugen-visudyne-lucentis/Move+Over+Macugen%2C+Visudyne+%26amp%3B+Lucentis%3F2006-08-13+16%3A59%3A00admin

Do not miss out on the Colorado Bioscience Association Finance Seminar on 27 July. Topics to be covered include accounting issues associated with stock compensation, and valuation issues incoporating Black-Scholes and lattice models. Register (here)

• 108View 4 Comments...http://clsdf.com/2006/07/calling-all-quants/Calling+All+Quants%212006-07-24+14%3A01%3A00admin

Do not miss out on the 2nd Annual Venture Conference for the Northern Rockies, to be held on 24-25 August. The deadline for presenting companies at the Big Sky Venture Capital Conference is fast approaching. Deadline for submission: July 31st. There is a biotech track for companies seeking seed stage funding through mezzanine. Companies from [...]

• 107View 3 Comments...http://clsdf.com/2006/07/big-sky-venture-capital-conference/Big+Sky+Venture+Capital+Conference2006-07-20+19%3A27%3A00admin

Lot’s of news coming from Sirna Therapeutics Inc., this Monday morning. First RNAI announced today that the USPTO will issue U.S. Patent No. 7,022,828 on April 4, 2006. This is the first siRNA target patent issued in the United States and sets an important precedent for Sirna’s entire target patent portfolio. The patent covers any [...]

• 80View 1 Comment...http://clsdf.com/2006/04/sirna-shaking-it-up/Sirna+Shaking+It+Up2006-04-03+15%3A38%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), announced today that the U.S. Patent and Trademark Office has granted Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids. The patent broadly covers a process for the synthesis, deprotection and purification of nucleic acids with one or more ribonucleotides. This process is critical for the efficient [...]

• 48View 2 Comments...http://clsdf.com/2006/01/sirna-granted-patent-for-rnai-production/Sirna+Granted+Patent+for+RNAi+Production2006-01-24+14%3A36%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), is scheduled to present at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2006 at 4:00 p.m. PST. A live audio webcast of the presentation will be available at the Company’s web site at www.sirna.com. Sirna is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and [...]

• 45View 1 Comment...http://clsdf.com/2006/01/sirna-to-webcast-jp-morgan-presentation/Sirna+to+Webcast+JP+Morgan+Presentation2006-01-09+21%3A04%3A00admin

Sirna Therapeutics (NASDAQ: RNAI) rocketed yesterday, though naturally some profit taking is occurring today, following very encouraging news of the first demonstration of systemic siRNA efficacy at therapeutically relevant doses, results were published in Nature Biotechnology. The study demonstrated that Sirna’s chemically optimized and encapsulated siRNAs have high potency and prolonged duration of activity in [...]

• 17View 6 Comments...http://clsdf.com/2005/07/sirna-setting-the-stage/Sirna+Setting+the+Stage2005-07-28+01%3A46%3A00admin